Butenko A K
Lik Sprava. 1996 Jul-Sep(7-9):160-2.
To treat patients with an accurately verified peripheral T-cellular lymphoma presenting with a high degree malignancy, there has been used a new aggressive chemotherapeutic protocol "Bu". It is more effective than the well known protocol CHOP. 83% patients achieved complete remission as well as long-term survival. Immunophenotyping of cells of malignant lymphomas had been done before choosing the relevant chemotherapeutic treatment policy.
为治疗经准确确诊且具有高度恶性的外周 T 细胞淋巴瘤患者，采用了一种新的激进化疗方案“Bu”。它比著名的 CHOP 方案更有效。83%的患者实现了完全缓解以及长期生存。在选择相关化疗治疗策略之前，已对恶性淋巴瘤细胞进行了免疫表型分析。
